KR20190100878A - Composition for preventing, treating or improving obesity or obesity-related disease comprising extracts of Lindera obtusiloba Blume leaf - Google Patents
Composition for preventing, treating or improving obesity or obesity-related disease comprising extracts of Lindera obtusiloba Blume leaf Download PDFInfo
- Publication number
- KR20190100878A KR20190100878A KR1020190020181A KR20190020181A KR20190100878A KR 20190100878 A KR20190100878 A KR 20190100878A KR 1020190020181 A KR1020190020181 A KR 1020190020181A KR 20190020181 A KR20190020181 A KR 20190020181A KR 20190100878 A KR20190100878 A KR 20190100878A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- obesity
- leaf extract
- increase
- ginger
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 90
- 208000008589 Obesity Diseases 0.000 title claims abstract description 70
- 235000020824 obesity Nutrition 0.000 title claims abstract description 70
- 239000000203 mixture Substances 0.000 title claims abstract description 53
- 201000010099 disease Diseases 0.000 title claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 15
- 240000006370 Lindera obtusiloba Species 0.000 title abstract description 5
- 235000012857 Lindera obtusiloba Nutrition 0.000 title abstract description 5
- 239000008280 blood Substances 0.000 claims abstract description 38
- 210000004369 blood Anatomy 0.000 claims abstract description 38
- 235000000346 sugar Nutrition 0.000 claims abstract description 13
- 208000032928 Dyslipidaemia Diseases 0.000 claims abstract description 11
- 208000004930 Fatty Liver Diseases 0.000 claims abstract description 11
- 208000002705 Glucose Intolerance Diseases 0.000 claims abstract description 11
- 206010019708 Hepatic steatosis Diseases 0.000 claims abstract description 11
- 208000017170 Lipid metabolism disease Diseases 0.000 claims abstract description 11
- 208000010706 fatty liver disease Diseases 0.000 claims abstract description 11
- 201000009104 prediabetes syndrome Diseases 0.000 claims abstract description 11
- 231100000240 steatosis hepatitis Toxicity 0.000 claims abstract description 11
- 231100000304 hepatotoxicity Toxicity 0.000 claims abstract description 10
- 206010019851 Hepatotoxicity Diseases 0.000 claims abstract description 8
- 230000007686 hepatotoxicity Effects 0.000 claims abstract description 8
- 235000000665 Lycianthes asarifolia Nutrition 0.000 claims description 40
- 241000866517 Lycianthes asarifolia Species 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 35
- 241000234314 Zingiber Species 0.000 claims description 31
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 31
- 235000008397 ginger Nutrition 0.000 claims description 31
- 150000002632 lipids Chemical class 0.000 claims description 29
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 235000013305 food Nutrition 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 18
- 230000002265 prevention Effects 0.000 claims description 16
- 206010067125 Liver injury Diseases 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 14
- 238000000605 extraction Methods 0.000 claims description 14
- 231100000234 hepatic damage Toxicity 0.000 claims description 14
- 230000006872 improvement Effects 0.000 claims description 14
- 230000008818 liver damage Effects 0.000 claims description 14
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 12
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 12
- 210000005228 liver tissue Anatomy 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 10
- 230000002829 reductive effect Effects 0.000 claims description 9
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 8
- 206010010075 Coma hepatic Diseases 0.000 claims description 7
- 206010016654 Fibrosis Diseases 0.000 claims description 7
- 206010020772 Hypertension Diseases 0.000 claims description 7
- 230000007882 cirrhosis Effects 0.000 claims description 7
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 7
- 210000003608 fece Anatomy 0.000 claims description 7
- 201000001059 hepatic coma Diseases 0.000 claims description 7
- 208000007386 hepatic encephalopathy Diseases 0.000 claims description 7
- 231100000283 hepatitis Toxicity 0.000 claims description 7
- 208000006454 hepatitis Diseases 0.000 claims description 7
- 231100000334 hepatotoxic Toxicity 0.000 claims description 7
- 230000003082 hepatotoxic effect Effects 0.000 claims description 7
- 201000007270 liver cancer Diseases 0.000 claims description 7
- 208000014018 liver neoplasm Diseases 0.000 claims description 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 7
- 230000003612 virological effect Effects 0.000 claims description 7
- 206010002383 Angina Pectoris Diseases 0.000 claims description 6
- 201000001320 Atherosclerosis Diseases 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 208000005171 Dysmenorrhea Diseases 0.000 claims description 6
- 206010013935 Dysmenorrhoea Diseases 0.000 claims description 6
- 206010019280 Heart failures Diseases 0.000 claims description 6
- 208000031773 Insulin resistance syndrome Diseases 0.000 claims description 6
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 claims description 6
- 206010050296 Intervertebral disc protrusion Diseases 0.000 claims description 6
- 206010033128 Ovarian cancer Diseases 0.000 claims description 6
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 6
- 208000029742 colonic neoplasm Diseases 0.000 claims description 6
- 208000020694 gallbladder disease Diseases 0.000 claims description 6
- 210000001596 intra-abdominal fat Anatomy 0.000 claims description 6
- 210000004185 liver Anatomy 0.000 claims description 6
- 208000010125 myocardial infarction Diseases 0.000 claims description 6
- 201000008482 osteoarthritis Diseases 0.000 claims description 6
- 201000002859 sleep apnea Diseases 0.000 claims description 6
- 208000011580 syndromic disease Diseases 0.000 claims description 6
- 238000009423 ventilation Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 235000013376 functional food Nutrition 0.000 claims description 5
- 229940058015 1,3-butylene glycol Drugs 0.000 claims description 4
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 4
- 150000001298 alcohols Chemical class 0.000 claims description 4
- 235000019437 butane-1,3-diol Nutrition 0.000 claims description 4
- 230000036541 health Effects 0.000 claims description 4
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 4
- 239000012046 mixed solvent Substances 0.000 claims description 4
- 150000003626 triacylglycerols Chemical class 0.000 claims description 3
- 235000009200 high fat diet Nutrition 0.000 abstract description 83
- 230000000694 effects Effects 0.000 abstract description 35
- 230000004584 weight gain Effects 0.000 abstract description 8
- 235000019786 weight gain Nutrition 0.000 abstract description 8
- 235000005911 diet Nutrition 0.000 abstract description 7
- 230000037396 body weight Effects 0.000 abstract description 5
- 230000000378 dietary effect Effects 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 238000010172 mouse model Methods 0.000 abstract description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 31
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 31
- 239000008103 glucose Substances 0.000 description 29
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 24
- 241000699670 Mus sp. Species 0.000 description 19
- 235000021590 normal diet Nutrition 0.000 description 17
- 235000012000 cholesterol Nutrition 0.000 description 12
- 239000000796 flavoring agent Substances 0.000 description 11
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 10
- 108010082126 Alanine transaminase Proteins 0.000 description 10
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 9
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 9
- 238000009395 breeding Methods 0.000 description 8
- 230000001488 breeding effect Effects 0.000 description 8
- 235000013355 food flavoring agent Nutrition 0.000 description 8
- 230000008859 change Effects 0.000 description 6
- 230000002550 fecal effect Effects 0.000 description 6
- 230000007935 neutral effect Effects 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- 230000003579 anti-obesity Effects 0.000 description 5
- 150000003904 phospholipids Chemical class 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 4
- 235000010443 alginic acid Nutrition 0.000 description 4
- 229920000615 alginic acid Polymers 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229960002725 isoflurane Drugs 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000003442 weekly effect Effects 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000000883 anti-obesity agent Substances 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- -1 etc.) Substances 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000021588 free fatty acids Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 229940125710 antiobesity agent Drugs 0.000 description 2
- 239000002830 appetite depressant Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 235000006694 eating habits Nutrition 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000007056 liver toxicity Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000013227 male C57BL/6J mice Methods 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 230000000291 postprandial effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 238000002137 ultrasound extraction Methods 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 206010048909 Boredom Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 229940086609 Lipase inhibitor Drugs 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 235000021407 appetite control Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000013542 behavioral therapy Methods 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 235000013410 fast food Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 231100000849 liver cell damage Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001631 vena cava inferior Anatomy 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Botany (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 생강나무 잎 추출물을 유효성분으로 포함하는 비만 또는 비만 관련 합병증의 예방, 치료, 또는 개선용 조성물 등에 관한 것이다.The present invention relates to a composition for the prevention, treatment, or improvement of obesity or obesity-related complications comprising a ginger leaf extract as an active ingredient.
비만은 일반적으로 체내에 지방조직이 과다한 상태인 것을 의미하며, 음식물로 섭취한 에너지가 신체활동 등으로 소비한 에너지와 균형을 이루지 못하여 잉여의 에너지가 체지방으로 축적되는 현상이다. 비만은 유전적인 요인, 불규칙한 식습관이나 운동부족 또는 패스트푸드의 과다섭취 등에 의한 환경적 요인, 우울감, 지루감, 과다한 스트레스 등에 의한 심리적 요인, 갑상선이나 부신피질 호르몬 변화에 의한 병적인 요인 등 매우 다양한 원인에 의해 발생하는데, 최근 경제성장과 생활방식의 변화에 따라 식습관에도 많은 변화가 생겨 바쁜 현대인들은 패스트푸드 등의 고열량 식이와 적은 운동량으로 인하여 체중 및 비만이 증가하고 있는 추세이다.Obesity generally means that the body has an excessive amount of fat tissue, and the energy consumed by food is not balanced with the energy consumed by physical activity, so that surplus energy is accumulated as body fat. Obesity is a very diverse cause, including genetic factors, environmental factors caused by irregular eating habits, lack of exercise or excessive food intake, psychological factors caused by depression, boredom and excessive stress, and pathological factors caused by thyroid or corticosteroid changes. It is caused by the recent economic growth and lifestyle changes, many changes in eating habits, busy modern people are increasing in weight and obesity due to high calorie diet and fast exercise such as fast food.
비만은 그 자체의 위험성보다 비만으로 인해 유발될 수 있는 여러 합병증 때문에 그 심각성이 더욱 크게 인식되고 있으며, 오랜 시간에 걸쳐 에너지 불균형에 의해 체지방이 비정상적으로 많아지면 당뇨, 고지혈증, 심장병, 뇌졸중, 동맥경화증, 지방간 등의 각종 대사성 질환과 성인병이 유발된다. 또한, 비만에 의해 사회적 고립감이나 소외, 자신감 결여, 우울감과 같은 정신적 질환이 유발될 수 있으므로, 비만은 전 세계적으로 심각한 사회문제로 대두되고 있으며 비만의 예방 및 치료에 대한 필요성이 매우 중요하게 인식되고 있다. Obesity is perceived more seriously because of the many complications that can be caused by obesity than its own risk, and if body fat is abnormally increased due to energy imbalance over time, diabetes, hyperlipidemia, heart disease, stroke, arteriosclerosis And various metabolic diseases such as fatty liver and adult disease. In addition, since obesity can cause mental illnesses such as social isolation, alienation, lack of confidence, and depression, obesity is a serious social problem worldwide, and the need for prevention and treatment of obesity is very important. have.
비만은 식이요법, 규칙적인 운동과 더불어 행동요법과 같은 생활습관의 개선, 및 식욕 억제제와 지방 흡수 억제제와 같은 약물을 통해 치료할 수 있다. 비만은 만성 질환이기 때문에 약물치료를 시도하는 경우 장기간의 사용이 필요하며, 현재 국내에서 3개월 이상 장기간 사용이 허가된 제품으로는 식욕억제제인 시부트라민(sibutramine)과 지방분해효소 억제제인 올리스타트(orlistat)가 있다. 그러나 이러한 비만 치료 약물들은 대부분 중추신경계에 작용하여 식욕을 조절하는 향정신성의약품들이므로 두통 및 구토 등의 부작용을 동반하며 남용 우려 등의 문제점이 있다. 따라서 상기 시판중인 항비만제의 부작용을 해결할 수 있는 안정성이 높고 항비만 효과가 우수한 소재를 개발하기 위한 연구가 필요한 실정이다.Obesity can be treated with diet, regular exercise, lifestyle improvements such as behavioral therapy, and medications such as appetite suppressants and fat absorption inhibitors. Obesity is a chronic disease that requires long-term use when attempting medication. Currently, products approved for long-term use in Korea for more than three months include sibutramine, an appetite suppressant, and orlistat, an lipase inhibitor. There is). However, most of these anti-obesity drugs are psychotropic drugs that act on the central nervous system to control appetite, so they have side effects such as headache and vomiting and there are problems such as abuse. Therefore, there is a need for research to develop a material having high stability and excellent anti-obesity effect that can solve the side effects of the commercially available anti-obesity agents.
한편, 생강나무(Lindera obtusiloba)는 우리나라, 일본, 중국 등지에 분포하는 쌍떡잎식물 미나리아재비목 녹나무과의 낙엽관목이며, 높이는 2~3m 정도 자라고, 개화기는 3~4월이며 결실기는 9월이다. 열매로 기름을 짜서 부인들의 머릿기름으로 썼으며, 잎이나 가지를 꺾으면 생강냄새가 난다고 하여 생강나무라 부르고, 개동백나무 혹은 황매목이라고도 불린다. On the other hand, the ginger tree (Lindera obtusiloba) is a deciduous shrub of the dicotyledonous plant of the genus Amphitaceae, which is distributed in Korea, Japan, China, etc., grows about 2-3m in height, blooms in March to April, and the fruiting season is September. The fruit was squeezed with oil and used as the head oil of the wives. When the leaves or branches are broken, the smell of ginger is called Ginger Tree.
생강나무는 활혈(活血), 서근(舒筋), 소종(消腫) 등의 효능이 있으며, 타박상 어혈종통을 치료한다고 알려져 있고 주로 찧어서 상처부위에 붙인다. 주로 복통에 쓰며 해열제, 기침약으로도 쓴다고 알려져 있다. 종래에 생강나무 잎 추출물은 피부 미백에도 효과가 있는 것으로 밝혀졌으나, 생강나무 잎 추출물의 비만 예방, 치료, 또는 개선 효과에 대해서는 아직 알려진 바가 없다. Ginger tree has activity such as blood circulation, active muscle, small muscle, and small species, and it is known to treat bruises and blood stem pains. It is mainly used for abdominal pain and is known as an antipyretic and cough medicine. Ginger leaf extract has been found to have an effect on skin whitening, but there is no known effect on the prevention, treatment, or improvement of obesity.
이에, 본 발명자들은 생강나무 잎 추출물이 체중 증가를 억제하는 것을 확인하여, 비만의 예방, 치료, 또는 개선용 조성물로 이용될 수 있도록 하였으며, 체중 증가에 따라 유발되는 비만 관련 합병증의 예방, 치료, 또는 개선 용도로도 이용될 수 있도록 하였다. Accordingly, the present inventors confirmed that the ginger leaf extract inhibits weight gain, so that it can be used as a composition for the prevention, treatment, or improvement of obesity, the prevention, treatment of obesity-related complications caused by weight gain, Or it can be used for improvement purposes.
본 발명자들은 종래 항비만제의 문제점을 해결할 수 있는 안정성이 높고 항비만 효과가 우수한 비만 예방 또는 치료용 조성물을 개발하고자 노력한 결과, 고지방식이에 의해 비만이 유도된 마우스 모델에서 생강나무 잎 추출물을 고지방식이에 혼합하여 급여시키며 관찰하였을 경우, 본 발명의 생강나무 잎 추출물의 우수한 항비만 효과를 확인함으로써 이에 기초하여 본 발명을 완성하였다.The present inventors have attempted to develop a composition for preventing or treating obesity, which has high stability and excellent anti-obesity effect, which can solve the problems of the conventional anti-obesity agent. When mixed and fed to a high-fat diet when observed, the present invention was completed based on this by confirming the excellent anti-obesity effect of the ginger leaf extract of the present invention.
이에, 본 발명은 생강나무 잎 추출물을 유효성분으로 포함하는 비만 또는 비만 관련 합병증의 예방 또는 치료용 약학적 조성물을 제공하는 것을 목적으로 한다.Accordingly, an object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of obesity or obesity-related complications comprising a ginger leaf extract as an active ingredient.
또한, 본 발명은 생강나무 잎 추출물을 유효성분으로 포함하는 비만 또는 비만 관련 합병증의 예방 또는 개선용 식품 조성물을 제공하는 것을 목적으로 한다. In addition, an object of the present invention is to provide a food composition for the prevention or improvement of obesity or obesity-related complications comprising the ginger leaf extract as an active ingredient.
그러나 본 발명이 이루고자 하는 기술적 과제는 이상에서 언급한 과제에 제한되지 않으며, 언급되지 않은 또 다른 과제들은 아래의 기재로부터 당해 기술분야의 통상의 기술자에게 명확하게 이해될 수 있을 것이다.However, the technical problem to be achieved by the present invention is not limited to the above-mentioned problem, another task that is not mentioned will be clearly understood by those skilled in the art from the following description.
상기와 같은 목적을 달성하기 위하여, 본 발명은 생강나무 잎 추출물을 유효성분으로 포함하는 비만 또는 비만 관련 합병증의 예방 또는 치료용 약학적 조성물로서,In order to achieve the above object, the present invention as a pharmaceutical composition for the prevention or treatment of obesity or obesity-related complications comprising a ginger leaf extract as an active ingredient,
상기 비만 관련 합병증은 제2형 당뇨병; 인슐린저항성 증후군; 내당능장애; 내장지방 증후군; 이상지질혈증; 약물성 간 손상, 바이러스성 간 손상, 간염, 간경화, 간암 또는 간성혼수를 포함하는 간독성 질환; 고혈압; 뇌졸중; 동맥경화증; 심부전증; 협심증; 심근경색증; 지방간; 담낭질환; 수면 무호흡증; 통풍; 허리디스크; 골관절염; 월경 이상; 대장암; 유방암; 및 난소암으로 이루어진 군으로부터 선택되는 하나 이상인 것을 특징으로 하는, 약학적 조성물을 제공한다.Obesity-related complications include
또한, 본 발명은 생강나무 잎 추출물을 유효성분으로 포함하는 비만 또는 비만 관련 합병증의 예방 또는 개선용 식품 조성물로서, In addition, the present invention as a food composition for the prevention or improvement of obesity or obesity-related complications comprising a ginger leaf extract as an active ingredient,
상기 비만 관련 합병증은 제2형 당뇨병; 인슐린저항성 증후군; 내당능장애; 내장지방 증후군; 이상지질혈증; 약물성 간 손상, 바이러스성 간 손상, 간염, 간경화, 간암 또는 간성혼수를 포함하는 간독성 질환; 고혈압; 뇌졸중; 동맥경화증; 심부전증; 협심증; 심근경색증; 지방간; 담낭질환; 수면 무호흡증; 통풍; 허리디스크; 골관절염; 월경 이상; 대장암; 유방암; 및 난소암으로 이루어진 군으로부터 선택되는 하나 이상인 것을 특징으로 하는, 식품 조성물을 제공한다.Obesity-related complications include
본 발명의 다른 일구현예로서, 상기 조성물은 체중의 증가를 억제시킬 수 있다.In another embodiment of the present invention, the composition may inhibit the increase in weight.
본 발명의 또 다른 일구현예로서, 상기 조성물은 혈당 증가를 억제시킬 수 있다.In another embodiment of the present invention, the composition may inhibit the increase in blood glucose.
본 발명의 또 다른 일구현예로서, 상기 조성물은 혈장 지질농도 증가를 억제시킬 수 있다.In another embodiment of the present invention, the composition may inhibit the increase in plasma lipid concentration.
본 발명의 또 다른 일구현예로서, 상기 조성물은 간조직 지질 함량을 감소시킬 수 있다.In another embodiment of the present invention, the composition may reduce the liver tissue lipid content.
본 발명의 또 다른 일구현예로서, 상기 조성물은 혈장 간독성지표 증가를 억제시킬 수 있다.In another embodiment of the present invention, the composition may inhibit the increase of plasma hepatotoxicity indicator.
본 발명의 또 다른 일구현예로서, 상기 조성물은 분변으로의 중성지질 배출을 증가시킬 수 있다.In another embodiment of the present invention, the composition may increase neutral lipid excretion into the feces.
본 발명의 또 다른 일구현예로서, 상기 생강나무 잎 추출물은 생강나무 잎에 추출용매를 첨가한 후 추출하는 단계; 및 추출된 추출물을 감압농축한 후 동결건조 하는 단계; 를 통해 제조될 수 있다.As another embodiment of the present invention, the ginger tree leaf extract is extracted after adding the extraction solvent to the ginger tree leaves; And lyophilizing and then extracting the extracted extract under reduced pressure. It can be prepared through.
본 발명의 또 다른 일구현예로서, 상기 추출용매는 물, C1내지 C4의 저급알코올, n-헥산, 에틸아세테이트, 아세톤, 부틸아세테이트, 1,3-부틸렌 글리콜, 메틸렌클로라이드, 및 이들의 혼합용매로 구성된 군으로부터 선택된 1종일 수 있다.As another embodiment of the present invention, the extraction solvent is water, C 1 to C 4 lower alcohol, n-hexane, ethyl acetate, acetone, butyl acetate, 1,3-butylene glycol, methylene chloride, and these It may be one selected from the group consisting of a mixed solvent of.
본 발명의 또 다른 일구현예로서, 상기 식품 조성물은 건강기능식품 조성물일 수 있다.As another embodiment of the present invention, the food composition may be a dietary supplement composition.
또한, 본 발명은 상기 조성물을 개체에 투여하는 단계를 포함하는, 비만 또는 비만 관련 합병증의 예방 또는 치료 방법을 제공한다.The present invention also provides a method of preventing or treating obesity or obesity-related complications, comprising administering the composition to a subject.
또한, 본 발명은 상기 조성물의 비만 또는 비만 관련 합병증의 예방 또는 치료 용도를 제공한다.The present invention also provides a use of the composition for the prevention or treatment of obesity or obesity-related complications.
본 발명에 따른 생강나무 잎 추출물은 식이성 비만 유도 마우스 모델에서 고지방식이에 의한 체중 및 공복혈당의 증가를 억제시키며, 내당능 장애를 개선시키는 효과가 있음을 확인하였다. 나아가, 이상지질개선 효능 및 지방간 및 간독성 개선 효과를 구체적으로 확인하였다. 따라서, 생강나무 잎 추출물은 비만뿐만 아니라 체중 증가에 따라 유발될 수 있는 비만 관련 합병증의 예방, 치료, 또는 개선용 기능성 식품 및 의약품 개발 등에 유용하게 이용될 수 있을 것으로 기대된다.Ginger leaf extract according to the present invention was suppressed the increase in body weight and fasting blood glucose by high fat diet in dietary obesity-induced mouse model, it was confirmed that the effect of improving impaired glucose tolerance. Furthermore, the effects of dyslipidemia and the improvement of fatty liver and hepatotoxicity were specifically identified. Therefore, the ginger leaf extract is expected to be useful for the development of functional foods and medicines for prevention, treatment, or improvement of obesity-related complications that can be caused by weight gain as well as obesity.
도 1은 본 발명의 일구현예에 따른 생강나무 잎 추출물의 항비만 효과를 평가하기 위하여 식이성 비만 유도 마우스 모델을 이용한 실험 디자인을 간략하게 나타낸 도면이다.
도 2는 본 발명의 일구현예에 따른 정상식이군(ND), 고지방식이군(HFD) 마우스들의 체중을 4주 동안 일주일 간격으로 측정하여 비만이 잘 유도되었는지를 확인한 후, 4주차에 고지방식이군(HFD)을 다시 고지방식이군(HFD) 및 생강나무 잎 추출물 급여군(LOL)으로 나누어 10주 동안 마우스들의 체중을 측정하여 사육기간에 따른 체중감소 및 체중증가 억제 효능을 비교하여 나타낸 도면이다.
도 3은 본 발명의 일구현예에 따른 정상식이군(ND), 고지방식이군(HFD) 마우스들의 공복혈당을 4주 동안 측정하여 고지방식이에 따른 공복혈당 증가를 관찰한 후, 4주차에 고지방식이군(HFD)을 다시 고지방식이군(HFD) 및 생강나무 잎 추출물 급여군(LOL)으로 나누어 8주 동안 4주일 간격으로 마우스들의 공복 혈당을 측정하여 사육기간에 따른 공복혈당 증가 억제 변화를 비교하여 나타낸 도면이다.
도 4는 본 발명의 일구현예에 따른 정상식이군(ND), 고지방식이군(HFD), 및 생강나무 잎 추출물 급여군(LOL) 마우스들의 식후 혈당농도 변화를 측정하고자 당부하 검사를 실시하여, 혈당 측정 0분의 혈당 농도를 100으로 기준하여 각 시간대별 혈당 농도를 보여주는 결과를 나타낸 도면이다.
도 5는 본 발명의 일구현예에 따른 정상식이군(ND), 고지방식이군(HFD), 및 생강나무 잎 추출물 급여군(LOL) 마우스들의 혈장 지질농도 측정 결과를 나타낸 도면이다.
도 6은 본 발명의 일구현예에 따른 정상식이군(ND), 고지방식이군(HFD), 및 생강나무 잎 추출물 급여군(LOL) 마우스들의 간조직 지질 프로파일 변화를 나타낸 도면이다.
도 7은 본 발명의 일구현예에 따른 정상식이군(ND), 고지방식이군(HFD), 및 생강나무 잎 추출물 급여군(LOL) 마우스들의 혈중 간독성 지표를 비교하여 나타낸 도면이다.
도 8은 본 발명의 일구현예에 따른 정상식이군(ND), 고지방식이군(HFD), 및 생강나무 잎 추출물 급여군(LOL) 마우스들의 분변 중성지질 변화를 비교하여 나타낸 도면이다. 1 is a diagram briefly showing an experimental design using a dietary obesity-induced mouse model to evaluate the anti-obesity effect of ginger tree leaf extract according to an embodiment of the present invention.
Figure 2 is the normal diet group (ND), high fat diet group (HFD) according to an embodiment of the present invention by measuring the weight of the mice at a weekly interval for 4 weeks, after confirming that the obesity is well induced, high-fat diet group at 4 weeks (HFD) is divided into a high-fat diet group (HFD) and ginger leaf extract feeding group (LOL) to measure the weight of the mice for 10 weeks to compare the weight loss and weight gain inhibitory effect according to the breeding period.
Figure 3 measured the fasting blood glucose of the normal diet group (ND), high-fat diet group (HFD) mice according to an embodiment of the present invention for 4 weeks after observing the increase in fasting glucose according to the high-fat diet, notices at 4 weeks HFD was divided into high-fat diet (HFD) and ginger leaf extract feeding group (LOL) to measure fasting blood glucose levels of mice at 4 week intervals for 8 weeks to compare the change in inhibition of fasting blood glucose increase according to breeding period. The figure shown.
4 is a sugar load test to measure the post-prandial blood sugar concentration change of the normal diet group (ND), high fat diet group (HFD), and ginger tree leaf extract feeding group (LOL) mice according to an embodiment of the present invention, Blood glucose measurement is a diagram showing the results showing the blood sugar concentration for each time based on the blood sugar concentration of 100 minutes.
Figure 5 is a view showing the plasma lipid concentration measurement results of the normal diet group (ND), high fat diet group (HFD), and ginger leaf extract feeding group (LOL) mice according to an embodiment of the present invention.
Figure 6 is a diagram showing the changes in the liver tissue lipid profile of normal diet group (ND), high fat diet group (HFD), and ginger leaf extract feeding group (LOL) mice according to an embodiment of the present invention.
Figure 7 is a view showing a comparison of blood liver toxicity indices of the normal diet group (ND), high fat diet group (HFD), and ginger leaf extract feeding group (LOL) mice according to an embodiment of the present invention.
Figure 8 is a view showing a comparison of fecal neutral lipid changes of the normal diet group (ND), high fat diet group (HFD), and ginger leaf extract feeding group (LOL) mice according to an embodiment of the present invention.
본 발명은 생강나무 잎 추출물을 유효성분으로 포함하는 비만 또는 비만 관련 합병증의 예방 또는 치료용 약학적 조성물로서,The present invention is a pharmaceutical composition for the prevention or treatment of obesity or obesity-related complications comprising a ginger leaf extract as an active ingredient,
상기 비만 관련 합병증은 제2형 당뇨병; 인슐린저항성 증후군; 내당능장애; 내장지방 증후군; 이상지질혈증; 약물성 간 손상, 바이러스성 간 손상, 간염, 간경화, 간암 또는 간성혼수를 포함하는 간독성 질환; 고혈압; 뇌졸중; 동맥경화증; 심부전증; 협심증; 심근경색증; 지방간; 담낭질환; 수면 무호흡증; 통풍; 허리디스크; 골관절염; 월경 이상; 대장암; 유방암; 및 난소암으로 이루어진 군으로부터 선택되는 하나 이상인 것을 특징으로 하는, 약학적 조성물을 제공한다.Obesity-related complications include
본 발명의 예방 또는 치료 대상 질병인 "비만(obesity)"은, 대사 장애로 인하여 체내에 지방세포가 증식 분화하고 이로 인하여 지방이 과잉으로 축적된 상태를 의미하며, 고혈압, 당뇨, 및 이상지질혈증 등을 동반하는 대사증후군을 포함하는 관련 합병증을 유발할 수 있다. 에너지 흡수량이 소비량에 비해 상대적으로 증가하는 경우, 지방세포의 수와 부피가 증가되는 과정을 거쳐 결과적으로 지방조직의 질량이 증가된다.The obesity, which is a disease to be prevented or treated according to the present invention, refers to a state in which fat cells proliferate and differentiate due to metabolic disorders, and thus fat is excessively accumulated, and hypertension, diabetes mellitus, and dyslipidemia Associated complications, including metabolic syndrome, may be caused. When energy absorption increases relative to consumption, the mass and volume of fat cells increase, resulting in an increase in the mass of fat tissue.
본 발명의 구체적인 실험예에 따르면, 상기 비만 관련 합병증은 제2형 당뇨병; 내당능장애; 이상지질혈증; 약물성 간 손상, 바이러스성 간 손상, 간염, 간경화, 간암 또는 간성혼수를 포함하는 간독성 질환; 또는 지방간일 수 있으나, 이에 제한되지 않는다. According to a specific experimental example of the present invention, the obesity-related complications are
본 발명에서 사용되는 용어 "예방"은, 본 발명에 따른 약학적 조성물의 투여에 의해 비만 또는 비만 관련 합병증을 억제시키거나 발병을 지연시키는 모든 행위를 의미한다.As used herein, the term "prevention" means any action that inhibits or delays the development of obesity or obesity-related complications by administration of a pharmaceutical composition according to the invention.
본 발명에서 사용되는 용어 "치료"는, 본 발명에 따른 약학적 조성물의 투여에 의해 비만 또는 비만 관련 합병증에 대한 증세가 호전되거나 이롭게 변경되는 모든 행위를 의미한다.As used herein, the term "treatment" refers to any action in which symptoms for obesity or obesity-related complications improve or benefit altered by administration of a pharmaceutical composition according to the invention.
또한, 본 발명은 상기 약학적 조성물을 개체에 투여하는 단계를 포함하는 비만 또는 비만 관련 합병증의 예방 또는 치료 방법을 제공한다.The present invention also provides a method for preventing or treating obesity or obesity-related complications comprising administering the pharmaceutical composition to a subject.
본 발명에서 사용되는 용어 "투여"는 임의의 적절한 방법으로 개체에게 소정의 본 발명의 조성물을 제공하는 것을 의미한다.As used herein, the term "administration" means providing a subject with any of the compositions of the present invention in any suitable manner.
본 발명에서 사용되는 용어 "개체"란 질병의 치료를 필요로 하는 대상을 의미하고, 보다 구체적으로는, 인간 또는 비-인간인 영장류, 생쥐(mouse), 개, 고양이, 말, 및 소 등의 포유류를 의미한다.As used herein, the term "individual" refers to a subject in need of treatment of a disease, and more specifically, human or non-human primates, mice, dogs, cats, horses, cattle, and the like. Mean mammal.
또한, 본 발명은 상기 약학적 조성물의 비만 또는 비만 관련 합병증의 예방 또는 치료용도를 제공한다.In addition, the present invention provides a use of the pharmaceutical composition for the prevention or treatment of obesity or obesity-related complications.
본 발명에서 "추출물"은, 상기 생강나무 잎의 추출처리에 의하여 얻어지는 추출액, 상기 추출액의 희석액이나 농축액, 상기 추출액을 건조하여 얻어지는 건조물, 상기 추출액의 조정제물이나 정제물, 또는 이들의 혼합물 등, 추출액 자체 및 추출액을 이용하여 형성 가능한 모든 제형의 추출물을 포함한다.In the present invention, the "extract" is an extract obtained by the extraction process of the ginger tree leaves, a diluent or concentrate of the extract, a dried product obtained by drying the extract, a crude or purified product of the extract, or a mixture thereof, It includes the extract itself and extracts of all formulations that can be formed using the extract.
본 발명의 상기 생강나무 잎 추출물에 있어서, 상기 생강나무 잎을 추출하는 방법은 특별히 제한되지 아니하며, 당해 기술분야에서 통상적으로 사용하는 방법에 따라 추출할 수 있다. 상기 추출 방법의 비제한적인 예로는, 열수 추출법, 초음파 추출법, 여과법, 환류 추출법 등을 들 수 있으며, 이들은 단독으로 수행되거나 2 종 이상의 방법을 병용하여 수행될 수 있다. In the ginger tree leaf extract of the present invention, the method of extracting the ginger tree leaf is not particularly limited, and may be extracted according to methods commonly used in the art. Non-limiting examples of the extraction method, hot water extraction method, ultrasonic extraction method, filtration method, reflux extraction method and the like, these may be carried out alone or in combination of two or more methods.
본 발명에서 상기 생강나무 잎을 추출하는 데에 사용되는 추출 용매의 종류는 특별히 제한되지 아니하며, 천연물로부터 추출물을 추출하는 당업계에 공지된 통상적인 방법에 따라, 즉, 통상적인 온도, 압력의 조건 하에서 통상적인 용매를 사용하여 추출할 수 있다. 예컨대, 본 발명에서 생강나무 잎 추출물은 물, 탄소 수 1 내지 4의 저급 알코올, n-헥산, 에틸아세테이트, 아세톤, 부틸아세테이트, 1,3-부틸렌 글리콜, 메틸렌클로라이드, 및 이들의 혼합 용매로 이루어진 군으로부터 선택된 1종 이상의 용매를 사용하여 추출할 수 있다. The type of the extraction solvent used to extract the ginger leaf in the present invention is not particularly limited, and according to a conventional method known in the art for extracting the extract from natural products, that is, the conditions of the usual temperature, pressure Extraction may be carried out using conventional solvents. For example, the ginger leaf extract in the present invention is water, lower alcohol having 1 to 4 carbon atoms, n-hexane, ethyl acetate, acetone, butyl acetate, 1,3-butylene glycol, methylene chloride, and a mixed solvent thereof It can be extracted using one or more solvents selected from the group consisting of.
상기 제조된 추출물은 이후 여과하거나 농축 또는 건조과정을 수행하여 용매를 제거할 수 있으며, 여과, 농축 및 건조를 모두 수행할 수 있다. 예컨대, 여과는 여과지를 이용하거나 감압여과기를 이용할 수 있으며, 농축은 감압 농축기, 건조는 동결건조법 등을 수행할 수 있으나, 이에 제한되는 것은 아니다.The prepared extract can then be filtered or concentrated or dried to remove the solvent, it can be carried out both filtration, concentration and drying. For example, the filtration may use a filter paper or a vacuum filter, the concentration may be a vacuum concentrator, the drying may be a freeze-drying method, but is not limited thereto.
본 발명의 일실험예에서는 상기 방법으로 추출한 생강나무 잎 추출물의 항비만 효과를 평가하기 위하여, 식이성 비만 유도 마우스 모델을 이용하여 실험을 진행하였다.In one experimental example of the present invention, to evaluate the anti-obesity effect of the ginger tree leaf extract extracted by the above method, the experiment was conducted using a dietary obesity-induced mouse model.
본 발명의 일실험예에서는, 수컷 C57BL/6J 마우스를 정상식이군(ND) 및 고지방식이군(HFD)으로 분류하여 4주 동안 사육하면서 체중을 측정한 결과 고지방식이군(HFD)이 정상식이군(ND)에 비해 체중이 급격히 증가하여 비만이 유도된 것을 관찰하였다. 이 후, 4주차 시점에서 고지방식이군(HFD)을 다시 고지방식이군(HFD) 및 생강나무 잎 추출물 급여군(LOL)으로 분류하여 10주 동안 사육하며 체중을 측정한 결과, 생강나무 잎 추출물 급여군(LOL)의 경우 고지방식이 대조군에 비해 증가된 체중을 감소시켰을 뿐만 아니라 체중증가를 억제하는 것을 관찰함으로써 생강나무 잎 추출물이 체중 감량에 효과가 있음을 확인하였다 (실험예 1 및 도 2 참조).In one experimental example of the present invention, male C57BL / 6J mice were classified into a normal diet group (ND) and a high fat diet group (HFD), and the weight was measured while breeding for 4 weeks, and the high fat diet group (HFD) was a normal diet group (ND). Obesity was induced by a sharp increase in body weight compared to). After 4 weeks, the high-fat diet group (HFD) was again classified into the high-fat diet group (HFD) and ginger leaf extract feeding group (LOL), and reared for 10 weeks, and weighed. In the case of the group (LOL), it was confirmed that the ginger leaf extract has an effect on weight loss by observing that the high-fat diet not only reduced the increased weight but also suppressed the weight gain (see Experimental Examples 1 and 2). ).
본 발명의 다른 실험예에서는, 정상식이군(ND), 고지방식이군(HFD) 마우스들의 공복혈당을 4주 동안 측정하여 고지방식이에 따른 공복혈당증가를 관찰한 후, 4주차에 고지방식이군(HFD)을 다시 고지방식이군 및 생강나무 잎 추출물 급여군(LOL)으로 나누어 8주 동안 4주일 간격으로 마우스들의 공복 혈당을 측정하여 사육기간에 따른 공복혈당 증가 억제 변화를 비교한 결과 생강나무 잎 추출물 급여군(LOL)의 경우 고지방식이군(HFD)에 비해 공복혈당 증가를 억제시키는 것을 확인하였다 (실험예 2 및 도 3 참조).In another experimental example of the present invention, the fasting glucose level of the normal diet group (ND) and the high-fat diet group (HFD) mice was measured for 4 weeks, and the fasting glucose level was observed according to the high-fat diet. HFD) was divided into high-fat diet and Ginger leaf extract feeding group (LOL) and measured fasting blood glucose levels of mice at 4 week intervals for 8 weeks. In the case of the payroll group (LOL), it was confirmed that the fasting blood glucose increase was suppressed compared to the high fat diet group (HFD) (see Experimental Example 2 and FIG. 3).
본 발명의 또 다른 실험예에서는, 상기 각 마우스 군에서 복강 내 포도당 투여 후 혈당 농도 변화를 분석한 결과 생강나무 잎 추출물 급여군(LOL)의 경우 내당능이 증가하여, 내당능 장애를 개선시킬 수 있음을 확인하였다(실험예 3 및 도 4 참조).In another experimental example of the present invention, the results of analyzing the blood glucose concentration change after intraperitoneal glucose administration in each mouse group in the case of ginger tree leaf extract feeding group (LOL) increased glucose tolerance, it is possible to improve impaired glucose tolerance It confirmed (see Experimental example 3 and FIG. 4).
본 발명의 또 다른 실험예에서는, 상기 각 마우스 군들을 희생시키고 복부하대정맥으로부터 채취한 혈액에서 혈장 지질농도 분석을 한 결과 생강나무 잎 추출물 급여군(LOL)의 경우 고지방식이군(HFD)에 비해 혈장 총 콜레스테롤, 인지질, 유리지방산 및 nonHDL-cholesterol 농도 증가를 억제시키는 것을 확인하였다(실험예 4 및 도 5 참조).In another experimental example of the present invention, plasma lipid concentration analysis was performed on blood collected from the subabdominal vena cava at the expense of the respective mouse groups, compared to the high-fat diet group (HFD) for the ginger leaf extract feeding group (LOL). Plasma total cholesterol, phospholipids, free fatty acids and nonHDL-cholesterol concentration was confirmed to inhibit the increase (see Experimental Example 4 and Figure 5).
본 발명의 또 다른 실험예에서는, 각 군의 마우스들의 간조직을 적출하여 간조직 중성지질 및 콜레스테롤 농도를 비교하여 분석한 결과 생강나무 잎 추출물 급여군(LOL)의 경우 고지방식이군(HFD)에 비해 간조직 중성지질 및 총 콜레스테롤 증가를 억제시키는 것을 확인하였다(실험예 5 및 도 6 참조). In another experimental example of the present invention, the liver tissue of each group of mice was extracted and analyzed by comparing the liver tissue triglycerides and cholesterol concentrations in the case of ginger tree leaf extract fed group (LOL) in the high-fat diet group (HFD) In comparison, it was confirmed that hepatic tissue neutral lipid and total cholesterol increase were inhibited (see Experimental Example 5 and FIG. 6).
또한, 각 군의 마우스들의 동일한 방법으로 채취한 혈액에서 간독성 지표인 GOT(glutamic oxaloacetic transaminase) 및 GPT(glutamic pyruvic transaminase)를 분석한 결과 생강나무 잎 추출물 급여군(LOL)에서 고지방식이군(HFD)에 비해 현저하게 낮은 혈중 GOT 및 GPT를 나타낸 것을 확인하였다(실험예 6 및 도 7).In addition, GOT (glutamic oxaloacetic transaminase) and GPT (glutamic pyruvic transaminase), which are indicators of hepatotoxicity, were analyzed in blood collected by the same method of mice in each group. It was confirmed that significantly lower blood GOT and GPT compared to (Experimental Example 6 and Figure 7).
본 발명의 또 다른 실험예에서는, 각 군의 마우스들의 분변을 수집하여 분변 중성지질 함량을 측정한 결과 생강나무 잎 추출물 급여군(LOL)의 분변 중성지질 함량이 고지방식이군(HFD)에 비해 유의적으로 증가하여 지질 배출이 증가하였음을 확인하였다(실험예 7 및 도 8).In another experimental example of the present invention, the fecal triglyceride content of the mice in each group was collected and fecal triglyceride content of Ginger leaf extract fed group (LOL) was significantly higher than the high fat diet group (HFD) As a result, it was confirmed that the lipid release increased (Experimental Example 7 and FIG. 8).
따라서, 본 발명의 실험예 결과를 통하여 생강나무 잎 추출물이 체중 및 공복혈당 증가 억제 효과 및 내당능 장애 개선 효과를 가지는 것을 알 수 있었다. 또한, 본 발명의 생강나무 잎 추출물은 혈장 지질농도 증가를 억제시킴으로써 이상지질개선 효능을 나타내며, 간조직 지질 함량 및 혈장 간독성지표인 GOT(glutamic oxaloacetic transaminase)와 GPT(glutamic pyruvic transaminase)의 증가를 억제시키고 분변으로의 중성지질 배출을 증가시킴으로써 지방간 및 간독성 개선 효과를 가짐을 알 수 있었다.Therefore, the results of the experimental example of the present invention was found that the ginger leaf extract has an effect of inhibiting the increase in body weight and fasting glucose and improving the impaired glucose tolerance. In addition, the ginger leaf extract of the present invention exhibits an improvement in dyslipidemia by inhibiting an increase in plasma lipid concentration, and inhibits an increase in hepatic lipid content and plasma hepatotoxicity markers (GOT) and glutamic pyruvic transaminase (GPT). And increased triglyceride output to feces was found to have an effect of improving liver and liver toxicity.
한편, 본 발명에서 "약학적 조성물"은 질병의 예방 또는 치료를 목적으로 제조된 것을 의미하며, 각각 통상의 방법에 따라 다양한 형태로 제형화하여 사용될 수 있다. 예컨대, 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽 등의 경구형 제형으로 제형화할 수 있고, 외용제, 좌제 및 멸균 주사용액의 형태로 제형화하여 사용할 수 있다. On the other hand, the "pharmaceutical composition" in the present invention means that is prepared for the purpose of preventing or treating a disease, each can be used in formulated in various forms according to conventional methods. For example, it may be formulated in oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, and syrups, and may be formulated in the form of external preparations, suppositories, and sterile injectable solutions.
또한, 본 발명의 약학적 조성물은 유효성분 이외에 약학적으로 허용되는 담체를 포함할 수 있다. 이때, 약제학적으로 허용되는 담체는 제제 시에 통상적으로 이용되는 것으로서, 락토스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 전분, 아카시아고무, 인산칼슘, 알기네이트, 젤라틴, 규산칼슘, 미세결정성 셀룰로스, 폴리비닐피로리돈, 셀룰로스, 물, 시럽, 메틸 셀룰로스, 메틸히드록시벤조에이트, 프로필 히드록시벤조에이트, 활석, 스테아르산 마그네슘 및 미네랄 오일 등을 포함하나, 이에 한정되는 것은 아니다. 또한, 상기성분들 이외에 윤활제, 습윤제, 감미제, 향미제, 유화제, 현탁제, 보존제 등을 추가로 포함할 수 있다.In addition, the pharmaceutical composition of the present invention may include a pharmaceutically acceptable carrier in addition to the active ingredient. At this time, the pharmaceutically acceptable carrier is commonly used in the preparation, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose , Polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate and mineral oil, and the like. In addition to the above components, it may further include a lubricant, wetting agent, sweetener, flavoring agent, emulsifier, suspending agent, preservative and the like.
본 발명의 약학적 조성물은 목적하는 방법에 따라 경구 투여하거나 비경구투여(예를 들어, 정맥 내, 피하, 복강 내 또는 국소에 적용)할 수 있으며, 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 시간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다.The pharmaceutical compositions of the present invention can be administered orally or parenterally (eg, applied intravenously, subcutaneously, intraperitoneally or topically) according to the desired method, and the dosage is determined by the condition and weight of the patient, Depending on the extent, drug form, route of administration, and time, it may be appropriately selected by those skilled in the art.
본 발명의 약학적 조성물은 약학적으로 유효한 양으로 투여한다. 본 발명에 있어서 "약학적으로 유효한 양"은 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분한 양을 의미하며, 유효용량 수준은 환자의 질환의 종류, 중증도, 약물의 활성, 약물에 대한 민감도, 투여 시간, 투여 경로 및 배출비율, 치료기간, 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다. 본 발명에 따른 약학적 조성물은 개별 치료제로 투여하거나 다른 치료제와 병용하여 투여될 수 있고 종래의 치료제와는 순차적 또는 동시에 투여될 수 있으며, 단일 또는 다중 투여될 수 있다. 상기 요소들을 모두 고려하여 부작용 없이 최소한의 양으로 최대 효과를 얻을 수 있는 양을 투여하는 것이 중요하며, 이는 당업자에 의해 용이하게 결정될 수 있다.The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. As used herein, the term “pharmaceutically effective amount” means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level refers to the type of disease, the severity, the activity of the drug, It may be determined according to the sensitivity to the drug, the time of administration, the route of administration and the rate of release, the duration of treatment, factors including the drug used concurrently and other factors well known in the medical field. The pharmaceutical compositions according to the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered as single or multiple doses. Taking all of the above factors into consideration, it is important to administer an amount that can achieve the maximum effect with a minimum amount without side effects, which can be readily determined by one skilled in the art.
또한, 본 발명은 생강나무 잎 추출물을 유효성분으로 포함하는 비만 또는 비만 관련 합병증의 예방 또는 개선용 식품 조성물로서, In addition, the present invention as a food composition for the prevention or improvement of obesity or obesity-related complications comprising a ginger leaf extract as an active ingredient,
상기 비만 관련 합병증은 제2형 당뇨병; 인슐린저항성 증후군; 내당능장애; 내장지방 증후군; 이상지질혈증; 약물성 간 손상, 바이러스성 간 손상, 간염, 간경화, 간암 또는 간성혼수를 포함하는 간독성 질환; 고혈압; 뇌졸중; 동맥경화증; 심부전증; 협심증; 심근경색증; 지방간; 담낭질환; 수면 무호흡증; 통풍; 허리디스크; 골관절염; 월경 이상; 대장암; 유방암; 및 난소암으로 이루어진 군으로부터 선택되는 하나 이상인 것을 특징으로 하는, 식품 조성물을 제공한다.Obesity-related complications include
본 발명에 있어서, 상기 식품 조성물은 건강기능식품 조성물일 수 있으나, 이에 제한되지 않는다.In the present invention, the food composition may be a health functional food composition, but is not limited thereto.
본 발명에서 사용되는 용어 "개선"은, 치료되는 상태와 관련된 파라미터, 예를 들면 증상의 정도를 적어도 감소시키는 모든 행위를 의미한다. 이 때 상기 건강기능식품 조성물은 비만 또는 비만 관련 합병증의 예방 또는 개선을 위하여 해당 질환의 발병 단계 이전 또는 발병 후, 치료를 위한 약제와 동시에 또는 별개로서 사용될 수 있다.As used herein, the term "improvement" refers to any action that at least reduces the parameters associated with the condition being treated, for example the extent of symptoms. At this time, the health functional food composition may be used simultaneously or separately with the agent for treatment before or after the onset of the disease in order to prevent or improve obesity or obesity-related complications.
본 발명에서 "건강기능식품 조성물"은, 담체, 희석제, 부형제 및 첨가제 중 하나 이상을 포함하여 정제, 환제, 산제, 과립제, 분말제, 캡슐제 및 액제 제형으로 이루어진 군에서 선택된 하나로 제형된 것을 특징으로 한다. In the present invention, the "health food composition" is characterized in that it is formulated as one selected from the group consisting of tablets, pills, powders, granules, powders, capsules and liquid formulations, including one or more of carriers, diluents, excipients and additives. It is done.
본 발명의 추출물에 첨가 할 수 있는 식품으로는, 각종 식품류, 분말, 과립, 정제, 캡슐, 시럽제, 음료, 껌, 차, 비타민 복합제, 건강 기능성 식품류 등이 있다. 상기 본 발명에 더 포함될 수 있는 첨가제로는, 천연 탄수화물, 향미제, 영양제, 비타민, 광물(전해질), 풍미제(합성 풍미제, 천연 풍미제 등), 착색제, 충진제, 팩트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH조절제, 안정화제, 방부제, 산화 방지제, 글리세린, 알코올, 탄산화제, 및 과육으로 이루어진 군으로부터 선택된 1종 이상의 성분을 사용할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토오스, 수크로오스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트리톨 등의 당알코올이다. 상기 향미제로서 천연 향미제(타우마틴, 스테비아추출물(예를 들어 레바우디오시드 A, 글리시르히진 등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. Foods that can be added to the extract of the present invention include various foods, powders, granules, tablets, capsules, syrups, beverages, gums, teas, vitamin complexes, and health functional foods. As additives which may be further included in the present invention, natural carbohydrates, flavoring agents, nutrients, vitamins, minerals (electrolytes), flavoring agents (synthetic flavoring agents, natural flavoring agents, etc.), colorants, fillers, pactic acid and salts thereof, Alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, antioxidants, glycerin, alcohols, carbonation agents, and one or more components selected from the group consisting of pulp can be used. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As the flavoring agent, natural flavoring agents (tauumatin, stevia extract (for example, rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used.
상기 외에 본 발명에 따른 조성물은 여러 가지 영양제, 비타민, 광물 (전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제, 팩트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. In addition to the above, the composition according to the present invention includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and neutralizing agents, fact acids and salts thereof, alginic acid and salts thereof, organic acids, protection Sex colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages and the like.
그밖에 본 발명에 다른 조성물은 천연 과일 주스 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. In addition, other compositions of the present invention may contain pulp for the production of natural fruit juices and vegetable beverages. These components can be used independently or in combination.
상기 담체, 부형제, 희석제 및 첨가제의 구체적인 예로는 이에 한정하는 것은 아니나, 락토오스, 덱스트로즈, 수크로오스, 솔비톨, 만니톨, 에리스리톨, 전분, 아카시아 고무, 인산칼슘, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 미세결정성 셀룰로오스, 폴리비닐키롤리돈, 셀룰로오스, 폴리비닐피로리돈, 메틸셀룰로오스, 물, 설탕시럽, 메틸 하이드록시 벤조에이트, 프로필하이드록시 벤조에이트, 활석, 스테아르산 마그네슘, 및 미네랄 오일로 이루어진 그룹으로부터 선택된 1종 이상이 사용되는 것이 바람직하다.Specific examples of the carrier, excipient, diluent and additives include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, erythritol, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium phosphate, calcium silicate, Group consisting of microcrystalline cellulose, polyvinylchirrolidone, cellulose, polyvinylpyrrolidone, methylcellulose, water, sugar syrup, methyl hydroxy benzoate, propylhydroxy benzoate, talc, magnesium stearate, and mineral oil It is preferred that at least one selected from be used.
이하, 본 발명의 이해를 돕기 위하여 바람직한 실시예 및 실험예를 제시한다. 그러나 하기의 실시예 및 실험예는 본 발명을 보다 쉽게 이해하기 위하여 제공되는 것일 뿐, 하기 실시예 및 실험예에 의해 본 발명의 내용이 한정되는 것은 아니다.Hereinafter, preferred examples and experimental examples are presented to help understand the present invention. However, the following Examples and Experimental Examples are provided only to more easily understand the present invention, and the contents of the present invention are not limited by the following Examples and Experimental Examples.
실시예 1. 생강나무 잎 추출물의 제조Example 1 Preparation of Ginger Leaf Extract
생강나무 잎에 70%의 주정추출용매를 첨가한 후, 30℃에서 5시간 이상 초음파 추출하였으며, 추출횟수는 4회로 하였다. 이를 감압농축한 후 동결건조 시켜 생강나무 잎 추출물을 제조하였으며, 생강나무 잎 추출물의 수율은 28.52%로 산출되었다. After the 70% alcohol extraction solvent was added to the leaves of ginger, ultrasonic extraction was performed at 30 ° C. for at least 5 hours, and the extraction frequency was 4 times. The extract was concentrated under reduced pressure and lyophilized to prepare a ginger leaf extract. The yield of the ginger leaf extract was calculated to be 28.52%.
실시예Example 2. 통계적 분석 2. Statistical Analysis
통계적 분석은 t-test에 의해 수행되었으며, 모든 실험 결과는 p<0.05일 때 통계적으로 유의한 차이를 나타내는 것으로 간주하였다.Statistical analysis was performed by t-test, and all experimental results were considered to show statistically significant difference when p <0.05.
(HFD vs. ND: *p<0.05, **p<0.01, ***p<0.001; HFD vs. LOL: #p<0.05, ##p<0.01, ###p<0.001)(HFD vs. ND: * p <0.05, ** p <0.01, *** p <0.001; HFD vs. LOL: #p <0.05, ## p <0.01, ### p <0.001)
실험예 1. 생강나무 잎 추출물에 의한 체중 변화 분석Experimental Example 1. Analysis of body weight change by the ginger leaf extract
식이성 비만 유도 마우스 모델에서 상기 실시예 1에서 제조한 생강나무 잎 추출물 섭취가 체중 증가에 미치는 영향을 알아보기 위하여, 도 1에 나타낸 모식도와 같이 실험을 디자인하여 진행하였다. 구체적으로, 4주령의 수컷 C57BL/6J 마우스(n=32)를 미국 잭슨사로부터 구입하여 일주일 동안 Lab chow로 적응 사육시키고, 정상식이군(ND, n=10) 및 고지방식이군(HFD, n=22)으로 분류하여 4주동안 사육하며 일주일 간격으로 체중을 측정함으로써 비만이 잘 유도되었음을 관찰하였다. 이후 사육 4주차 시점에 고지방식이군(HFD, n=22)을 다시 고지방식이군(HFD, n=12) 및 생강나무 잎 추출물 급여군(LOL, 1%의 생강나무 잎 추출물+고지방식이, n=10)으로 분류하여 10주 동안 사육하며 일주일 간격으로 체중을 측정하였다.In order to determine the effect of the ginger tree leaf extract ingestion prepared in Example 1 on weight gain in a dietary obesity-induced mouse model, the experiment was designed and designed as shown in Figure 1. Specifically, four-week-old male C57BL / 6J mice (n = 32) were purchased from Jackson, USA, and adapted to breed in Lab chow for one week, normal diet group (ND, n = 10) and high fat diet group (HFD, n = It was observed that obesity was well induced by breeding for 4 weeks and weighing at weekly intervals. After 4 weeks of breeding high-fat diet group (HFD, n = 22), high-fat diet group (HFD, n = 12) and ginger tree leaf extract supplement group (LOL, 1% ginger tree leaf extract + high fat diet, n = 10) were bred for 10 weeks and weighed at weekly intervals.
그 결과, 도 2에 나타낸 바와 같이, 고지방식이군(HFD)의 경우 정상식이군(ND)과 비교하여 체중이 급격하게 증가한 것에 반해 생강나무 잎 추출물 급여군(LOL)의 경우 급여 9주차부터 고지방식이에 의해 증가된 체중을 유의적으로 감소시키는 것을 관찰하였다.As a result, as shown in Figure 2, in the case of high-fat diet group (HFD) compared to the normal diet group (ND) body weight was increased sharply, whereas in the case of ginger tree leaf extract pay group (LOL)
실험예 2. 생강나무 잎 추출물이 혈당 변화에 미치는 영향 분석Experimental Example 2 Analysis of the Effect of Ginger Leaf Extract on Glucose Changes
상기 실험예 1의 결과를 통하여 상기 실시예 1에서 제조한 생강나무 잎 추출물의 섭취가 체중을 감소시키는 효과가 있음을 확인하였으므로, 이에 더하여 혈당 변화에도 영향을 미치는지 알아보고자 하였다. 이를 위해, 상기 실험예 1의 방법으로 4주 사육기간 동안 마우스를 12시간 동안 절식시키고 꼬리에서 채혈하여 공복 혈당을 측정함으로써 고지방식이에 의한 혈당상승을 관찰한 후, 사육 4주차 시점에 고지방식이군을 다시 고지방식이군(HFD) 및 생강나무 잎 추출물 급여군(LOL)으로 분류하여 8주 사육기간 동안 상기와 같은 방법으로 공복 혈당을 측정하였다. It was confirmed through the results of Experimental Example 1 that the intake of the ginger tree leaf extract prepared in Example 1 has an effect of reducing weight, and in addition to this it was to determine whether it affects the blood sugar change. To this end, the mice were fasted for 12 hours during the four-week breeding period by the method of Experimental Example 1, blood was collected from the tail, and fasting blood glucose was measured. This group was again divided into high-fat diet group (HFD) and ginger leaf extract feeding group (LOL) and fasting blood glucose was measured in the same manner as described above for 8 weeks breeding period.
그 결과, 도 3에 나타낸 바와 같이, 고지방식이군(HFD)의 경우 정상식이군(ND)에 비해 유의적으로 증가된 혈당 수치를 유지한 반면, 생강나무 잎 추출물 급여군(LOL)의 경우에는 8주 동안의 사육기간 전반에 걸쳐 고지방식이군에 비해 낮은 혈당 수치를 유지하는 것을 확인하였다. 상기 결과를 통해, 생강나무 잎 추출물이 탁월한 혈당강하 효과가 있음을 알 수 있었다. As a result, as shown in Figure 3, the high-fat diet group (HFD) maintained a significantly increased blood sugar level compared to the normal diet group (ND), while in the case of ginger leaf extract supplement group (LOL) 8 It was confirmed that the high-fat diet maintained lower blood glucose levels during the weekly breeding period. Through the above results, it was found that the ginger leaf extract has an excellent hypoglycemic effect.
실험예 3. 생강나무 잎 추출물이 내당능에 미치는 영향 분석Experimental Example 3 Analysis of the Effect of Ginger Leaf Extract on Glucose Tolerance
식후 혈당 농도 변화를 측정하고자 상기 실험예 1의 방법으로 마우스를 12시간 절식시킨 후 포도당 용액을 체중 kg당 0.5g씩 복강내로 투여한 뒤, 각각 0, 30, 60, 120 분 시간별로 꼬리정맥을 통해 채혈하여 혈당을 측정하였다. 혈당 측정 0분의 혈당 농도를 100으로 기준하여 각 시간대별 혈당 농도를 나타내었다.After the meal, the mice were fasted for 12 hours by the method of
그 결과, 도 5에 나타낸 바와 같이, 모든 실험군의 혈당은 당부하 30분 후에 최고치를 나타낸 후 60분후에 점차 감소되었으며, 생강나무잎 추출물 급여군(LOL)의 혈당은 모든 시간대에서 고지방식이군(HFD)에 비해 유의적으로 감소하였다. 상기로부터, 생강나무잎 추출물을 식이 보충할 경우 고지방식이로 인한 식후 혈당을 유의적으로 감소시켜 내당능을 개선 시킴을 확인하였다. As a result, as shown in Figure 5, the blood sugar of all the experimental group showed a maximum after 30 minutes of glucose load gradually decreased after 60 minutes, the blood sugar of the Ginger Leaf Extract feeding group (LOL) was high-fat diet group (all times) Significantly reduced compared to HFD). From the above, it was confirmed that the supplementation of ginger tree leaf extract significantly improves glucose tolerance by significantly reducing postprandial blood sugar due to high fat diet.
실험예 4. 생강나무 잎 추출물이 혈장 지질농도에 미치는 영향 분석Experimental Example 4 Analysis of the Effect of Ginger Leaf Extract on Plasma Lipid Concentration
상기 실험예 1의 체중 변화 분석에 대하여 상기 실시예 1에서 제조한 생강나무 잎 추출물 섭취가 혈장 지질 농도에 미치는 영향을 알아보고자 하였다. 이를 위해, 상기 실험예 1의 방법으로 14주간 사육한 각 군의 마우스들을 12시간 동안 절식시키고 이소플루란(isoflurane)(Baxter, USA) 흡입을 통해 마취한 후 희생시키고 복부하대정맥으로부터 혈액을 채취하였다. 채취한 혈액은 heparin으로 처리한 후, 1,000×g, 4℃에서 15분간 원심 분리한 후 혈장을 수집하였고 시료 분석 시까지 70℃에 보관하였다. 보관한 혈장으로부터 혈장 총 콜레스테롤 (cholesterol), 인지질, 유리지방산 및 nonHDL-cholesterol 함량을 비교하였으며, 이 때, 혈장 총 콜레스테롤 함량은 효소법을 응용한 측정용 시액 (Asan kit, Korea)를 사용하였고, 유리지방산 및 인지질 함량은 Wako enzymatic kit (Wako Chemicals, USA)를 사용하였다. 혈장 nonHDL-cholesterol의 함량은 혈장 총 콜레스테롤과 HDL-cholesterol의 차이를 계산하였다. For the weight change analysis of Experimental Example 1, we tried to find out the effect of the ginger leaf extract intake prepared in Example 1 on the plasma lipid concentration. To this end, mice of each group bred for 14 weeks by the method of Experimental Example 1 were fasted for 12 hours, sacrificed after anesthesia through inhalation with isoflurane (isoflurane) (Baxter, USA), and blood was collected from the inferior vena cava It was. The collected blood was treated with heparin, centrifuged at 1,000 × g and 4 ° C. for 15 minutes, and then plasma was collected and stored at 70 ° C. until sample analysis. Plasma total cholesterol (cholesterol), phospholipids, free fatty acids and nonHDL-cholesterol contents were compared from the stored plasma, and the plasma total cholesterol content was measured using an enzyme-based measuring solution (Asan kit, Korea). Fatty acid and phospholipid content was used with Wako enzymatic kit (Wako Chemicals, USA). Plasma nonHDL-cholesterol content calculated the difference between plasma total cholesterol and HDL-cholesterol.
그 결과, 도 5에 나타낸 바와 같이, 고지방식이군(HFD)의 경우 정상식이군(ND)에 비해 혈장 총 콜레스테롤 (cholesterol), 인지질 및 nonHDL-cholesterol 함량이 모두 증가한 반면, 생강나무 잎 추출물 급여군(LOL)의 경우에는 고지방식이군(HFD)에 비해 혈장 총 콜레스테롤, 인지질, 유리지방산 및 nonHDL-cholesterol 농도를 유의적으로 감소시키는 것을 확인하였다. 따라서, 상기 결과로부터 생강나무 잎 추출물이 이상지질 개선 효능을 가짐을 알 수 있었다. As a result, as shown in Figure 5, the high-fat diet group (HFD) increased the total cholesterol (cholesterol), phospholipids and nonHDL-cholesterol content of the normal diet group (ND), while the ginger leaf extract supplement group ( LOL) significantly reduced plasma total cholesterol, phospholipids, free fatty acids and nonHDL-cholesterol concentrations compared to the high-fat diet group (HFD). Therefore, it can be seen from the above results that the ginger tree leaf extract has an abnormal lipid improving effect.
실험예 5. 생강나무 잎 추출물이 간조직 지질프로파일에 미치는 영향 분석Experimental Example 5. Effect of Ginger Leaf Extract on Liver Lipid Profiles
상기 실시예 1에서 제조한 생강나무 잎 추출물 섭취가 간조직 지질농도에 미치는 영향을 알아보고자, 상기 실험예 1의 방법으로 14주간 사육한 각 군의 마우스들을 12시간 동안 절식시키고 이소플루란(isoflurane)(Baxter, USA) 흡입을 통해 마취한 후 희생시키고 장기들을 적출하였다. 적출한 각 마우스의 간, 신장, 및 근육 조직을 인산완충액(PBS; phosphate buffered saline)으로 여러 번 헹구고 물기를 제거하여 중량을 측정하였다. 각 조직은 적출 즉시 액체 질소에 급냉시켜 시료 분석 시까지 70℃에서 보관하였다.To determine the effect of the ginger tree leaf extract ingestion prepared in Example 1 on liver tissue lipid concentration, each group of mice bred for 14 weeks by the method of Experimental Example 1 was fasted for 12 hours and isoflurane (isoflurane (Baxter, USA) Anesthetized via inhalation, sacrificed and organs removed. Liver, kidney, and muscle tissue of each mouse was rinsed several times with phosphate buffered saline (PBS) and drained to determine the weight. Each tissue was quenched in liquid nitrogen immediately after extraction and stored at 70 ° C. until sample analysis.
그 후, 적출한 간 조직을 chloroform : methanol(1:1) 용매로 지질을 추출하고 37℃에서 질소 가스로 휘발시켜 isopropanol로 희석한 후 지질 정량을 위해 효소 시액에 유화제로 3 mM cholic acid (sodium salt)와 0.5% Triton X-100을 혼합하였다. 간의 중성지질 및 총 콜레스테롤 함량은 Asan enzymatic kits (Asan, Seoul)를 이용하여 측정하였다. Then, the extracted liver tissue was extracted with a chloroform: methanol (1: 1) solvent, volatilized with nitrogen gas at 37 ° C, diluted with isopropanol, and 3 mM cholic acid (sodium) as an emulsifier in the enzyme solution for quantification of lipids. salt) and 0.5% Triton X-100. Hepatic triglyceride and total cholesterol content were measured using Asan enzymatic kits (Asan, Seoul).
그 결과, 도 6에 나타낸 바와 같이, 고지방식이군(HFD)의 경우 정상식이군(ND)에 비해 뚜렷하게 증가된 간조직 중성지질 및 총 콜레스테롤 함량을 나타낸 반면, 생강나무 잎 추출물 급여군(LOL)의 경우에는 고지방식이군(HFD)에 비해 간조직 지질함량이 유의적으로 감소한 것을 확인하였다. 따라서, 상기 결과로부터 생강나무 잎 추출물이 지방간 개선 효능을 가짐을 알 수 있었다. As a result, as shown in Figure 6, the high-fat diet group (HFD) showed a significantly increased liver tissue triglyceride and total cholesterol content compared to the normal diet group (ND), while the ginger leaf extract supplement group (LOL) In case of liver fat, liver lipid content was significantly reduced compared to high fat diet group (HFD). Therefore, it can be seen from the above results that ginger tree leaf extract has fatty liver improvement effect.
실험예 6. 생강나무 잎 추출물이 간조직 독성에 미치는 영향 분석Experimental Example 6. Effect of Ginger Leaf Extract on Liver Tissue Toxicity
상기 실험예 5의 결과를 통하여 생강나무 잎 추출물 섭취가 간 조직 지질농도를 감소시키는 효과가 있음을 확인하였으므로, 이에 더하여 간세포 손상과 밀접한 관련이 있는 GOT(glutamic oxaloacetic transaminase)와 GPT(glutamic pyruvic transaminase) 활성도를 분석하고자 하였다. 이를 위해, 상기 실험예 4의 방법으로 수집한 혈액으로부터 혈장 GOT 및 GPT를 효소법을 이용한 측정용 시액(Asan kit, Korea)을 사용하여 측정하였다. The results of
그 결과, 도 7에 나타낸 바와 같이, 고지방식이군(HFD)의 경우 정상식이군(ND)에 비해 유의적으로 증가된 혈장 GOT 및 GPT 함량을 나타낸 반면, 생강나무 잎 추출물 급여군(LOL)의 경우에는 고지방식이군(HFD)에 비해 혈장 GOT 및 GPT 함량이 현저하게 감소하는 것을 확인하였다. 따라서, 상기 결과로부터 생강나무 잎 추출물이 간독성을 억제시키는 효능을 가짐을 알 수 있었다. As a result, as shown in Figure 7, the high-fat diet group (HFD) showed significantly increased plasma GOT and GPT content compared to the normal diet group (ND), whereas the ginger leaf extract feed group (LOL) It was confirmed that the plasma GOT and GPT content is significantly reduced compared to the high fat diet group (HFD). Therefore, it can be seen from the above results that ginger tree leaf extract has the effect of inhibiting hepatotoxicity.
실험예 7. 생강나무 잎 추출물이 분변 중성지질에 미치는 영향 분석Experimental Example 7 Analysis of the Effect of Ginger Leaf Extract on Fecal Neutral Lipid
본 발명의 생강나무 잎 추출물 섭취가 분변으로의 지질 배출에 미치는 영향을 분석하기 위하여, 상기 실험예 5의 방법으로 분변에서 지질 성분을 추출한 후 분변 중성지질 함량을 Asan enzymatic kits(Asan, Seoul)를 이용하여 정량하였다. In order to analyze the effect of ginger tree leaf extract intake of the present invention on the excretion of lipid into feces, extract the lipid component in feces by the method of Experimental Example 5 to determine the fecal neutral lipid content of Asan enzymatic kits (Asan, Seoul) Quantification was carried out using.
그 결과, 도 8에 나타낸 바와 같이, 고지방식이군(HFD)의 경우 정상식이군(ND)과 유의적인 차이를 보이지 않았으나 생강나무 잎 추출물 급여군(LOL)의 분변 중성지질 농도가 고지방식이군(HFD)에 비해 유의적으로 증가하였다. 따라서, 상기로부터, 생강나무 잎 추출물을 식이 보충할 경우 분변으로의 중성지방 배출을 증가시켜 간조직 지질 농도 개선에 기여함을 알 수 있었다. As a result, as shown in Figure 8, the high-fat diet group (HFD) did not show a significant difference from the normal diet group (ND), but the concentration of fecal neutral lipids in the Ginger leaf extract feed group (LOL) high-fat diet group (HFD) Significantly increased). Therefore, it can be seen from the above that, when supplemented with ginger tree leaf extract, triglyceride excretion to feces was increased to contribute to improving liver tissue lipid concentration.
전술한 본 발명의 설명은 예시를 위한 것이며, 본 발명이 속하는 기술분야의 통상의 지식을 가진 자는 본 발명의 기술적 사상이나 필수적인 특징을 변경하지 않고서 다른 구체적인 형태로 쉽게 변형이 가능하다는 것을 이해할 수 있을 것이다. 그러므로 이상에서 기술한 실시예 및 실험예들은 모든 면에서 예시적인 것이며 한정적이 아닌 것으로 이해해야 한다. The foregoing description of the present invention is intended for illustration, and it will be understood by those skilled in the art that the present invention may be easily modified in other specific forms without changing the technical spirit or essential features of the present invention. will be. Therefore, it should be understood that the embodiments and the experimental examples described above are illustrative in all respects and are not restrictive.
Claims (19)
상기 비만 관련 합병증은 제2형 당뇨병; 인슐린저항성 증후군; 내당능장애; 내장지방 증후군; 이상지질혈증; 약물성 간 손상, 바이러스성 간 손상, 간염, 간경화, 간암 또는 간성혼수를 포함하는 간독성 질환; 고혈압; 뇌졸중; 동맥경화증; 심부전증; 협심증; 심근경색증; 지방간; 담낭질환; 수면 무호흡증; 통풍; 허리디스크; 골관절염; 월경 이상; 대장암; 유방암; 및 난소암으로 이루어진 군으로부터 선택되는 하나 이상인 것을 특징으로 하는, 약학적 조성물.
A pharmaceutical composition for preventing or treating obesity or obesity-related complications, comprising a ginger leaf extract as an active ingredient,
Obesity-related complications include type 2 diabetes; Insulin resistance syndrome; Impaired glucose tolerance; Visceral fat syndrome; Dyslipidemia; Hepatotoxic diseases including drug liver damage, viral liver damage, hepatitis, cirrhosis, liver cancer or hepatic coma; High blood pressure; stroke; Atherosclerosis; Heart failure; angina pectoris; Myocardial infarction; Fatty liver; Gallbladder disease; Sleep apnea; ventilation; Herniated disc; Osteoarthritis; Dysmenorrhea; Colon cancer; Breast cancer; And one or more selected from the group consisting of ovarian cancer, pharmaceutical composition.
상기 조성물은 체중의 증가를 억제시키는 것을 특징으로 하는, 약학적 조성물.
The method of claim 1,
The composition, characterized in that to inhibit the increase in weight, pharmaceutical composition.
상기 조성물은 혈당 증가를 억제시키는 것을 특징으로 하는, 약학적 조성물.
The method of claim 1,
The composition is characterized in that to suppress the increase in blood sugar, pharmaceutical composition.
상기 조성물은 혈장 지질농도 증가를 억제시키는 것을 특징으로 하는, 약학적 조성물.
The method of claim 1,
The composition, characterized in that to inhibit the increase in plasma lipid concentration, pharmaceutical composition.
상기 조성물은 간조직 지질 함량을 감소시키는 것을 특징으로 하는, 약학적 조성물.
The method of claim 1,
The composition is characterized in that for reducing the liver lipid content.
상기 조성물은 혈장 간독성지표 증가를 억제시키는 것을 특징으로 하는, 약학적 조성물.
The method of claim 1,
The composition is characterized in that to inhibit the increase in plasma hepatotoxicity indicator, pharmaceutical composition.
상기 조성물은 분변으로의 중성지질 배출을 증가시키는 것을 특징으로 하는, 약학적 조성물.
The method of claim 1,
The composition is characterized in that to increase the release of triglycerides to feces.
상기 생강나무 잎 추출물은 생강나무 잎에 추출용매를 첨가한 후 추출하는 단계; 및 추출된 추출물을 감압농축한 후 동결건조 하는 단계;
를 통해 제조되는 것을 특징으로 하는, 약학적 조성물.
The method of claim 1,
Extracting the ginger tree leaf extract after adding an extraction solvent to the ginger tree leaf; And lyophilizing and then extracting the extracted extract under reduced pressure.
Characterized in that prepared through, pharmaceutical composition.
상기 추출용매는 물, C1내지 C4의 저급알코올, n-헥산, 에틸아세테이트, 아세톤, 부틸아세테이트, 1,3-부틸렌 글리콜, 메틸렌클로라이드, 및 이들의 혼합용매로 구성된 군으로부터 선택된 1종인 것을 특징으로 하는, 약학적 조성물.
The method of claim 8,
The extraction solvent is one selected from the group consisting of water, C 1 to C 4 lower alcohols, n-hexane, ethyl acetate, acetone, butyl acetate, 1,3-butylene glycol, methylene chloride, and mixed solvents thereof. Characterized in that the pharmaceutical composition.
상기 비만 관련 합병증은 제2형 당뇨병; 인슐린저항성 증후군; 내당능장애; 내장지방 증후군; 이상지질혈증; 약물성 간 손상, 바이러스성 간 손상, 간염, 간경화, 간암 또는 간성혼수를 포함하는 간독성 질환; 고혈압; 뇌졸중; 동맥경화증; 심부전증; 협심증; 심근경색증; 지방간; 담낭질환; 수면 무호흡증; 통풍; 허리디스크; 골관절염; 월경 이상; 대장암; 유방암; 및 난소암으로 이루어진 군으로부터 선택되는 하나 이상인 것을 특징으로 하는, 식품 조성물.
As a food composition for the prevention or improvement of obesity or obesity-related complications, comprising a ginger leaf extract as an active ingredient,
Obesity-related complications include type 2 diabetes; Insulin resistance syndrome; Impaired glucose tolerance; Visceral fat syndrome; Dyslipidemia; Hepatotoxic diseases including drug liver damage, viral liver damage, hepatitis, cirrhosis, liver cancer or hepatic coma; High blood pressure; stroke; Atherosclerosis; Heart failure; angina pectoris; Myocardial infarction; Fatty liver; Gallbladder disease; Sleep apnea; ventilation; Herniated disc; Osteoarthritis; Dysmenorrhea; Colon cancer; Breast cancer; And one or more selected from the group consisting of ovarian cancer, food composition.
상기 조성물은 체중의 증가를 억제시키는 것을 특징으로 하는, 식품 조성물.
The method of claim 10,
The composition is characterized in that to suppress the increase in weight, food composition.
상기 조성물은 혈당 증가를 억제시키는 것을 특징으로 하는, 식품 조성물.
The method of claim 10,
The composition is characterized in that to suppress the increase in blood sugar, food composition.
상기 조성물은 혈장 지질농도 증가를 억제시키는 것을 특징으로 하는, 식품 조성물.
The method of claim 10,
The composition is characterized in that to inhibit the increase in plasma lipid concentration, food composition.
상기 조성물은 간조직 지질 함량을 감소시키는 것을 특징으로 하는, 식품 조성물.
The method of claim 10,
The composition is characterized in that reducing the liver tissue lipid content, food composition.
상기 조성물은 혈장 간독성지표 증가를 억제시키는 것을 특징으로 하는, 식품 조성물.
The method of claim 10,
The composition, characterized in that to inhibit the increase in plasma hepatotoxicity indicator, food composition.
상기 조성물은 분변으로의 중성지질 배출을 증가시키는 것을 특징으로 하는, 식품 조성물.
The method of claim 10,
The composition is characterized in that to increase the discharge of triglycerides to feces.
상기 생강나무 잎 추출물은 생강나무 잎에 추출용매를 첨가한 후 추출하는 단계; 및 추출된 추출물을 감압농축한 후 동결건조 하는 단계;
를 통해 제조되는 것을 특징으로 하는, 식품 조성물.
The method of claim 10,
Extracting the ginger tree leaf extract after adding an extraction solvent to the ginger tree leaf; And lyophilizing and then extracting the extracted extract under reduced pressure.
Characterized in that it is prepared through, a food composition.
상기 추출용매는 물, C1내지 C4의 저급알코올, n-헥산, 에틸아세테이트, 아세톤, 부틸아세테이트, 1,3-부틸렌 글리콜, 메틸렌클로라이드, 및 이들의 혼합용매로 구성된 군으로부터 선택된 1종인 것을 특징으로 하는, 식품 조성물.
The method of claim 17,
The extraction solvent is one selected from the group consisting of water, C 1 to C 4 lower alcohols, n-hexane, ethyl acetate, acetone, butyl acetate, 1,3-butylene glycol, methylene chloride, and mixed solvents thereof. Characterized in that the food composition.
상기 식품 조성물은 건강기능식품 조성물인 것을 특징으로 하는, 식품 조성물.
The method of claim 10,
The food composition is a health functional food composition, characterized in that the food composition.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180020596 | 2018-02-21 | ||
| KR20180020596 | 2018-02-21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20190100878A true KR20190100878A (en) | 2019-08-29 |
| KR102232330B1 KR102232330B1 (en) | 2021-03-26 |
Family
ID=67775763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020190020181A KR102232330B1 (en) | 2018-02-21 | 2019-02-21 | Composition for preventing, treating or improving obesity or obesity-related disease comprising extracts of Lindera obtusiloba Blume leaf |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102232330B1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050018701A (en) * | 2003-08-08 | 2005-02-24 | 강대식 | food and drug composition for lose in weight and cholesterol and manufacturing method |
| KR20090079584A (en) * | 2008-01-18 | 2009-07-22 | 양지화학 주식회사 | Composition Comprising the Extracts of Lindera obtusiloba for Prevention and Treatment of Cardiovascular Diseases |
| KR101209220B1 (en) | 2008-12-22 | 2012-12-06 | 경희대학교 산학협력단 | A composition containing Lindera obtusiloba leaf extract for skin whitening and wrinkle treatment |
-
2019
- 2019-02-21 KR KR1020190020181A patent/KR102232330B1/en active IP Right Grant
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050018701A (en) * | 2003-08-08 | 2005-02-24 | 강대식 | food and drug composition for lose in weight and cholesterol and manufacturing method |
| KR20090079584A (en) * | 2008-01-18 | 2009-07-22 | 양지화학 주식회사 | Composition Comprising the Extracts of Lindera obtusiloba for Prevention and Treatment of Cardiovascular Diseases |
| KR101209220B1 (en) | 2008-12-22 | 2012-12-06 | 경희대학교 산학협력단 | A composition containing Lindera obtusiloba leaf extract for skin whitening and wrinkle treatment |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102232330B1 (en) | 2021-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10398747B2 (en) | Composition comprising the extract of herbal combination for preventing or treating diabetic peripheral neuropathy | |
| KR101464337B1 (en) | Composition for anti-obesity comprising extract of Diospyros lotus as effective component | |
| KR102225574B1 (en) | Composition for preventing, treating or improving obesity or obesity-related disease comprising extracts of Angelica tenuissima | |
| JP2019513382A (en) | Composition for the prevention, amelioration or treatment of hyperuricemia or hyperuricemia-related metabolic disorders, which comprises the extract of Yuchichi as an active ingredient | |
| KR102064651B1 (en) | Composition for preventing or improving diabetes mellitus comprising momrdica charantia (l.) extract, chrysanthemum zawadskii var. latilobum and paeonia lactiflora extract as an effective ingredient | |
| KR101685876B1 (en) | Pharmaceutical composition comprising the extract of Platycodon grandiflorum for preventing or treating of obesity | |
| KR101910317B1 (en) | Composition for preventing, treating or improving obesity comprising extracts of Lycopus lucidus Turcz. | |
| CN108367039B (en) | Composition for treating or preventing liver disease comprising Citrullus spinosa extract as active ingredient | |
| KR101206543B1 (en) | A composition for preventing or treating of fatty liver comprising an extract of chestnut inner shell | |
| KR101942959B1 (en) | Compositions for prevention or treatment of diabete or diabetic complications comprising an extract or fractions of Actinidia arguta as active ingredient | |
| KR102232330B1 (en) | Composition for preventing, treating or improving obesity or obesity-related disease comprising extracts of Lindera obtusiloba Blume leaf | |
| WO2014133286A1 (en) | Composition containing extracts of artemisia iwayomogi and curcuma longa as active ingredients for preventing, inhibiting, or treating obesity-related diseases | |
| US11083767B2 (en) | Pharmaceutical composition comprising an extract of platycodon grandiflorum and method for preventing or treating of obesity using the same | |
| US10064908B2 (en) | Method for preventing, improving or treating liver disease | |
| KR101824329B1 (en) | Composition comprising the fraction of Moutan Cortex Radicis extract for preventing or treating liver disases | |
| WO2018066952A1 (en) | Composition comprising crassirhizomae rhizoma extract as active ingredient for preventing, alleviating, or treating hyperuricemia or hyperuricemia-related metabolic disorders | |
| KR102231713B1 (en) | Composition for preventing, treating or improving obesity or obesity-related disease comprising extracts of Mentha arvensis var. piperascens | |
| KR102627108B1 (en) | Pharmaceutical composition for preventing, improving or treating nonalcoholic fatty liver comprising mixture of Acer tegmentosum Maxim extract and mushroom extract as effective material and manufacturing method for the same | |
| KR100473529B1 (en) | Composition comprising an extract of sungisan crude drug complex as an effective ingredient for preventing and treating diabetes | |
| KR102291168B1 (en) | Compositions for the prevention or treatment of metabolic diseases containing extracts or fractions of Typha angustifolia | |
| CA2973962A1 (en) | Pharmaceutical composition comprising platycodon grandiflorum extract for preventing or treating obesity | |
| KR101081451B1 (en) | Composition for Preventing or Treating of Obesity Comprising Secoiridoid Derivatives as Active Ingredients | |
| KR101899086B1 (en) | Composition for preventing, improving or treating liver damage | |
| KR100478150B1 (en) | Health care food comprising an extract of the crude drug complex as an effective ingredient for preventing diabetes | |
| KR101759436B1 (en) | Composition comprising Pogostemonis Herba extract for preventing or treating liver damage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| X091 | Application refused [patent] | ||
| AMND | Amendment | ||
| X701 | Decision to grant (after re-examination) | ||
| GRNT | Written decision to grant |